{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T13:02:29Z","timestamp":1780318949707,"version":"3.54.1"},"reference-count":64,"publisher":"Oxford University Press (OUP)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1111\/j.1753-4887.2012.00479.x","type":"journal-article","created":{"date-parts":[[2012,5,30]],"date-time":"2012-05-30T16:13:50Z","timestamp":1338394430000},"page":"357-366","source":"Crossref","is-referenced-by-count":94,"title":["Niacin: chemical forms, bioavailability, and health effects"],"prefix":"10.1093","volume":"70","author":[{"given":"Douglas","family":"MacKay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Hathcock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erminia","family":"Guarneri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2012,5,30]]},"reference":[{"key":"10.1111\/j.1753-4887.2012.00479.x-BIB1|cit1","first-page":"442","volume-title":"Modern Nutrition in Health and Disease","author":"Burgeois","year":"2006"},{"key":"10.1111\/j.1753-4887.2012.00479.x-BIB2|cit2","first-page":"123","volume-title":"Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin, and Choline","author":"Standing Committee on the Scientific Evaluation of Dietary Reference Intakes and its Panel on Folate, Other B Vitamins, and Choline and Subcommittee on Upper Reference Levels of Nutrients","year":"1998"},{"key":"10.1111\/j.1753-4887.2012.00479.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/j.1365-2796.2005.01528.x","article-title":"Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review","volume":"258","author":"Carleson","year":"2005","journal-title":"J Intern Med."},{"key":"10.1111\/j.1753-4887.2012.00479.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/0003-9861(55)90070-9","article-title":"Influence of nicotinic acid on serum cholesterol in man","volume":"54","author":"Altschul","year":"1955","journal-title":"Arch Biochem Biophys."},{"key":"10.1111\/j.1753-4887.2012.00479.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"549","DOI":"10.2217\/17460875.1.5.549","article-title":"Effect of niacin on lipoproteins and atherosclerosis","volume":"1","author":"Ganji","year":"2006","journal-title":"Future Lipidol."},{"key":"10.1111\/j.1753-4887.2012.00479.x-BIB6|cit6","unstructured":"Scientific Committee on Food. European Commission Opinion of the Scientific Committee on Food on the Tolerable Upper Intake Levels of Nicotinic Acid and Nicotinamide (Niacin). SCF\/CS\/NUT\/UPPLEV\/39\/Final 2002 http:\/\/ec.europa.eu\/food\/fs\/sc\/scf\/out80j_en.pdf"},{"key":"10.1111\/j.1753-4887.2012.00479.x-BIB7|cit7","unstructured":"Expert Group on Vitamins and Minerals. Food Standards Agency Safe Upper Levels for Vitamins and Minerals 2003 http:\/\/cot.food.gov.uk\/pdfs\/vitmin2003.pdf"},{"key":"10.1111\/j.1753-4887.2012.00479.x-BIB8|cit8","first-page":"85","volume-title":"Vitamin and Mineral Safety","author":"Hathcock","year":"2004"},{"key":"10.1111\/j.1753-4887.2012.00479.x-BIB9|cit9","unstructured":"Food and Agriculture Organization of the United Nations (FAO) and the World Health Organization (WHO) A Model for Establishing Upper Levels of Intake for Nutrients and Related Substances: report of a Joint FAO\/WHO Technical Workshop on Food Nutrient Risk Assessment 2006 http:\/\/www.who.int\/ipcs\/highlights\/full_report.pdf"},{"key":"10.1111\/j.1753-4887.2012.00479.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/jps.2600660635","article-title":"GI absorption of niacin in humans","volume":"66","author":"Bechgaard","year":"1977","journal-title":"J Pharm Sci."},{"key":"10.1111\/j.1753-4887.2012.00479.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/0002-9343(92)90018-7","article-title":"Hepatic toxicity of unmodified and time-release preparations of niacin","volume":"92","author":"Rader","year":"1992","journal-title":"Am J Med."},{"key":"10.1111\/j.1753-4887.2012.00479.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1001\/jama.1938.02790510034009","article-title":"A reaction to the oral administration of nicotinic acid","volume":"11","author":"Sebrell","year":"1938","journal-title":"JAMA."},{"key":"10.1111\/j.1753-4887.2012.00479.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1001\/jama.1938.02790330004002","article-title":"The treatment of subclinical and classic pellagra. Use of nicotinic acid, nicotinic acid amide and sodium nicotinate, with special reference to the vasodilator action and the effect on mental symptoms","volume":"11","author":"Spies","year":"1938","journal-title":"JAMA."},{"key":"10.1111\/j.1753-4887.2012.00479.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/j.1520-037X.2006.04736.x","article-title":"\u201cFlush-free niacin\u201d: dietary supplement may be \u201cbenefit free","volume":"9","author":"Norris","year":"2006","journal-title":"Prev Cardiol."},{"key":"10.1111\/j.1753-4887.2012.00479.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1001\/archfami.5.10.567","article-title":"Clinical trial of wax-matrix sustained-release niacin in a Russian population with hypercholesterolemia","volume":"5","author":"Aronov","year":"1996","journal-title":"Arch Fam Med."},{"key":"10.1111\/j.1753-4887.2012.00479.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/bdd.555","article-title":"The comparative bioavailability of an extended-release niacin and lovastatin fixed dose combination tablet versus extended-release niacin tablet, lovastatin tablet and a combination of extended-release niacin tablet and lovastatin tablet","volume":"28","author":"Menon","year":"2007","journal-title":"Biopharm Drug Dispos."},{"key":"10.1111\/j.1753-4887.2012.00479.x-BIB17|cit17","first-page":"1","article-title":"Inositol hexanicotinate (inositol hexaniacinate) as a source of niacin (vitamin B3) added for nutritional purposes in food supplements. Scientific Opinion of the Panel on Food Additives and Nutrient Sources Added to Food","volume":"949","author":"European Food Safety Authority (EFSA)","year":"2009","journal-title":"EFSA J."},{"key":"10.1111\/j.1753-4887.2012.00479.x-BIB18|cit18","first-page":"1170","article-title":"On the elimination of unabsorbed hexanicotinic acid esters of meso-inositol in the feces","volume":"14","author":"Harthon","year":"1964","journal-title":"Arzneimittelforschung."},{"key":"10.1111\/j.1753-4887.2012.00479.x-BIB19|cit19","first-page":"9","article-title":"Inositol hexanicotinate for improved nicotinic acid therapy. Preliminary report","volume":"174","author":"Welsh","year":"1961","journal-title":"Int Record Med."},{"key":"10.1111\/j.1753-4887.2012.00479.x-BIB20|cit20","first-page":"1337","article-title":"Nicotinic acid level in the blood and fibrinolysis under the influence of hexanicotinate acid esters of m-inositol","volume":"15","author":"Sommer","year":"1965","journal-title":"Arzneimittelforschung."},{"key":"10.1111\/j.1753-4887.2012.00479.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/j.0954-6820.1968.tb10508.x","article-title":"Effect of a single dose of nicotinic acid on plasma lipids in patients with hyperlipoproteinemia","volume":"183","author":"Carlson","year":"1968","journal-title":"Acta Med Scand."},{"key":"10.1111\/j.1753-4887.2012.00479.x-BIB22|cit22","first-page":"1859","article-title":"Enzymatic hydrolysis of pentaerythritoltetranicotinate and meso-inositolhexanicotinate in blood and tissues","volume":"29","author":"Harthon","year":"1979","journal-title":"Arzneimittelforschung."},{"key":"10.1111\/j.1753-4887.2012.00479.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/BF00644960","article-title":"Nocturnal inhibition of lipolysis in man by nicotinic acid and derivatives","volume":"16","author":"Kruse","year":"1979","journal-title":"Eur J Clin Pharmacol."},{"key":"10.1111\/j.1753-4887.2012.00479.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.atherosclerosis.2005.08.025","article-title":"Accumulation of chylomicron remnants and impaired vascular reactivity occur in subjects with isolated low HDL cholesterol: effects of niacin treatment","volume":"187","author":"Benj\u00f3","year":"2006","journal-title":"Atherosclerosis."},{"key":"10.1111\/j.1753-4887.2012.00479.x-BIB25|cit25","doi-asserted-by":"crossref","first-page":"996","DOI":"10.7326\/0003-4819-139-12-200312160-00009","article-title":"Varying cost and free nicotinic acid content in over-the-counter niacin preparations for dyslipidemia","volume":"139","author":"Meyers","year":"2003","journal-title":"Ann Intern Med."},{"key":"10.1111\/j.1753-4887.2012.00479.x-BIB26|cit26","first-page":"336","volume-title":"Treatment of the Hyperlipidemic States","author":"Parsons","year":"1971"},{"key":"10.1111\/j.1753-4887.2012.00479.x-BIB27|cit27","first-page":"265","article-title":"Bioavailability of nicotinamide-rich powder obtained from bonito as niacin source in humans and rats [in Japanese]","volume":"56","author":"Fukuwatari","year":"2005","journal-title":"J Home Econ."},{"key":"10.1111\/j.1753-4887.2012.00479.x-BIB28|cit28","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1046\/j.1523-5408.2001.00005.x","article-title":"A review of Niaspan\u00ae, an extended-release niacin","volume":"4","author":"Abourjaily","year":"2001","journal-title":"Nutr Clin Care."},{"key":"10.1111\/j.1753-4887.2012.00479.x-BIB29|cit29","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1177\/1074248410361337","article-title":"Effect of niacin therapy on cardiovascular outcomes in patients with coronary artery disease","volume":"15","author":"Duggal","year":"2010","journal-title":"J Cardiovasc Pharmacol Ther."},{"key":"10.1111\/j.1753-4887.2012.00479.x-BIB30|cit30","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/0026-0495(85)90092-7","article-title":"Contrasting effects of unmodified and time-release forms of naicin on lipoproteins in hyperlipidemic subjects: clues to mechanism of action of niacin","volume":"34","author":"Knopp","year":"1985","journal-title":"Metabolism."},{"key":"10.1111\/j.1753-4887.2012.00479.x-BIB31|cit31","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1001\/jama.1994.03510330050033","article-title":"A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients","volume":"271","author":"McKenney","year":"1994","journal-title":"JAMA."},{"key":"10.1111\/j.1753-4887.2012.00479.x-BIB32|cit32","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1172\/JCI109385","article-title":"Effects of nicotinic acid therapy on plasma high density lipoprotein subfraction distribution and composition and on apolipoprotein A metabolism","volume":"63","author":"Shepherd","year":"1979","journal-title":"J Clin Invest."},{"key":"10.1111\/j.1753-4887.2012.00479.x-BIB33|cit33","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1365-2796.1990.tb00209.x","article-title":"Effects of nicotinic acid on serum cholesterol concentrations of high density lipoprotein subfractions HDL2 and HDL3 in hyperlipoproteinaemia","volume":"228","author":"Wahlberg","year":"1990","journal-title":"J Intern Med."},{"key":"10.1111\/j.1753-4887.2012.00479.x-BIB34|cit34","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/0021-9150(85)90041-3","article-title":"Levels of lipoprotein Lp(a) decline with neomycin and niacin treatment","volume":"57","author":"Gurakar","year":"1985","journal-title":"Atherosclerosis."},{"key":"10.1111\/j.1753-4887.2012.00479.x-BIB35|cit35","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1365-2796.1989.tb01393.x","article-title":"Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid","volume":"226","author":"Carlson","year":"1989","journal-title":"J Intern Med."},{"key":"10.1111\/j.1753-4887.2012.00479.x-BIB36|cit36","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/S0026-0495(98)90284-0","article-title":"Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia","volume":"47","author":"Knopp","year":"1998","journal-title":"Metabolism."},{"key":"10.1111\/j.1753-4887.2012.00479.x-BIB37|cit37","doi-asserted-by":"crossref","first-page":"29U","DOI":"10.1016\/S0002-9149(98)00732-2","article-title":"A new extended-release niacin (Niaspan): efficacy, tolerability, and safety in hypercholesterolemic patients","volume":"82","author":"Morgan","year":"1998","journal-title":"Am J Cardiol."},{"key":"10.1111\/j.1753-4887.2012.00479.x-BIB38|cit38","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1185\/030079906X89766","article-title":"Evaluation of the safety and tolerability of prolonged-release nicotinic acid in a usual care setting: the NAUTILUS study","volume":"22","author":"Vogt","year":"2006","journal-title":"Curr Med Res Opin."},{"key":"10.1111\/j.1753-4887.2012.00479.x-BIB39|cit39","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1001\/archinte.1991.00400070172024","article-title":"Niacin revisited. A randomized, controlled trial of wax-matrix sustained-release niacin in hypercholesterolemia","volume":"151","author":"Keenan","year":"1991","journal-title":"Arch Intern Med."},{"key":"10.1111\/j.1753-4887.2012.00479.x-BIB40|cit40","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1177\/030006057900700601","article-title":"An experimentally controlled evaluation of the effect of inositol nicotinate upon the digital blood flow in patients with Raynaud's phenomenon","volume":"7","author":"Holti","year":"1979","journal-title":"J Int Med Res."},{"key":"10.1111\/j.1753-4887.2012.00479.x-BIB41|cit41","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1177\/030006058501300604","article-title":"A double-blind placebo-controlled study of Hexopal in the treatment of intermittent claudication","volume":"13","author":"O'Hara","year":"1985","journal-title":"J Int Med Res."},{"key":"10.1111\/j.1753-4887.2012.00479.x-BIB42|cit42","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1177\/030006058100900601","article-title":"Quantitative thermal imaging to assess inositol nicotinate treatment for Raynaud's syndrome","volume":"9","author":"Ring","year":"1981","journal-title":"J Int Med Res."},{"key":"10.1111\/j.1753-4887.2012.00479.x-BIB43|cit43","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/BF02284056","article-title":"A double-blind randomised placebo-controlled trial of hexopal in primary Raynaud's disease","volume":"7","author":"Sunderland","year":"1988","journal-title":"Clin Rheumatol."},{"key":"10.1111\/j.1753-4887.2012.00479.x-BIB44|cit44","first-page":"176","article-title":"Inositol hexaniacinate: a safer alternative to niacin","volume":"1","author":"Head","year":"1995","journal-title":"Altern Med Rev."},{"key":"10.1111\/j.1753-4887.2012.00479.x-BIB45|cit45","first-page":"222","article-title":"Inositol hexaniacinate","volume":"3","author":"Head","year":"1998","journal-title":"Altern Med Rev."},{"key":"10.1111\/j.1753-4887.2012.00479.x-BIB46|cit46","first-page":"327","article-title":"Effects of hexanicotinate of meso-inositol in patients with primary hyperlipidemia [in Spanish]","volume":"30","author":"Agusti","year":"1978","journal-title":"Rev Invest Clin"},{"key":"10.1111\/j.1753-4887.2012.00479.x-BIB47|cit47","first-page":"585","article-title":"New drug combination for medical management of hyperlipidemia: clinical study [in German]","volume":"15","author":"Fischer","year":"1977","journal-title":"Int J Clin Pharmacol Biopharm."},{"key":"10.1111\/j.1753-4887.2012.00479.x-BIB48|cit48","first-page":"335","article-title":"Effect of calcium p-chlorphenoxyisobutyrate and calcium carbonate on plasma lipids and lipoproteins of patients with hyperlipoproteinaemia","volume":"9","author":"Koskinen","year":"1977","journal-title":"Ann Clin Res."},{"key":"10.1111\/j.1753-4887.2012.00479.x-BIB49|cit49","first-page":"359","article-title":"Comparative studies of the response of normolipemic and dyslipidemic aged subjects to two forms of delayed-action nicotinic acid polyesters. Pentaerythrotol tetranicotinate and inositol hexanicotinate. Results of a controlled cross-over trial [in Italian]","volume":"134","author":"Ziliotto","year":"1977","journal-title":"Arch Sci Med (Torino)."},{"key":"10.1111\/j.1753-4887.2012.00479.x-BIB50|cit50","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jacl.2010.03.047","article-title":"Extended-release nicotinic acid versus inositol hexanicotinate for the treatment of dyslipidemia","volume":"4","author":"Keenan","year":"2010","journal-title":"J Clin Lipidol."},{"key":"10.1111\/j.1753-4887.2012.00479.x-BIB51|cit51","first-page":"49","article-title":"Treatment of intermittent claudication with inositol nicotinate","volume":"230","author":"Head","year":"1986","journal-title":"Practitioner."},{"key":"10.1111\/j.1753-4887.2012.00479.x-BIB52|cit52","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/j.1742-1241.1988.tb08609.x","article-title":"The therapeutic efficacy of inositol nicotinate (Hexopal) in intermittent claudication: a controlled trial","volume":"42","author":"O'Hara","year":"1988","journal-title":"Br J Clin Pract."},{"key":"10.1111\/j.1753-4887.2012.00479.x-BIB53|cit53","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1177\/030006057700500401","article-title":"Quantitative thermographic assessment of inositol nicotinate therapy in Raynaud's phenomena","volume":"5","author":"Ring","year":"1977","journal-title":"J Int Med Res."},{"key":"10.1111\/j.1753-4887.2012.00479.x-BIB54|cit54","unstructured":"Genus Pharmaceuticals [package insert] Hexopal 500\u2003mg tablets http:\/\/www.medicines.org.uk\/EMC\/medicine\/16947\/SPC\/Hexopal%20500mg%20Tablets\/"},{"key":"10.1111\/j.1753-4887.2012.00479.x-BIB55|cit55","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1080\/10401230701653245","article-title":"Managing depression in geriatric populations","volume":"19","author":"Beyer","year":"2007","journal-title":"Ann Clin Psychiatry."},{"key":"10.1111\/j.1753-4887.2012.00479.x-BIB56|cit56","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s11883-000-0096-y","article-title":"Niacin dosing: relationship to benefits and adverse effects","volume":"2","author":"Capuzzi","year":"2000","journal-title":"Curr Atheroscler Rep."},{"key":"10.1111\/j.1753-4887.2012.00479.x-BIB57|cit57","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1097\/00004836-198710000-00022","article-title":"Nicotinic acid-induced fulminant hepatic failure","volume":"9","author":"Clementz","year":"1987","journal-title":"J Clin Gastroenterol."},{"key":"10.1111\/j.1753-4887.2012.00479.x-BIB58|cit58","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1007\/s001250051536","article-title":"Safety of high-dose nicotinamide: a review","volume":"43","author":"Knip","year":"2000","journal-title":"Diabetologia."},{"key":"10.1111\/j.1753-4887.2012.00479.x-BIB59|cit59","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1001\/jama.1969.03150200121025","article-title":"Adverse effects of niacin in emergent psychosis","volume":"207","author":"Hoffer","year":"1969","journal-title":"JAMA."},{"key":"10.1111\/j.1753-4887.2012.00479.x-BIB60|cit60","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S0140-6736(87)90250-9","article-title":"Nicotinamide may extend remission phase in insulin-dependent diabetes","volume":"329","author":"Vague","year":"1987","journal-title":"Lancet."},{"key":"10.1111\/j.1753-4887.2012.00479.x-BIB61|cit61","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1007\/BF00265087","article-title":"Effect of nicotinamide therapy upon B-cell function in newly diagnosed type-1 (insulin-dependent) diabetic patients","volume":"32","author":"Mendola","year":"1989","journal-title":"Diabetiologia."},{"key":"10.1111\/j.1753-4887.2012.00479.x-BIB62|cit62","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1007\/BF00404097","article-title":"A trial of nicotinamide in newly diagnosed patients with type 1 (insulin-dependent) diabetes mellitus","volume":"33","author":"Chase","year":"1990","journal-title":"Diabetologia."},{"key":"10.1111\/j.1753-4887.2012.00479.x-BIB63|cit63","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1007\/s001250050362","article-title":"Double blind trial of nicotinamide in recent-onset IDDM (the IMDIAB III study)","volume":"38","author":"Pozzilli","year":"1995","journal-title":"Diabetiologia."},{"key":"10.1111\/j.1753-4887.2012.00479.x-BIB64|cit64","doi-asserted-by":"crossref","first-page":"980","DOI":"10.2337\/diabetes.47.6.980","article-title":"The Deutsche Nicotinamide Intervention Study: an attempt to prevent type 1 diabetes. DENIS Group","volume":"47","author":"Lampeter","year":"1998","journal-title":"Diabetes."}],"container-title":["Nutrition Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/nutritionreviews\/article-pdf\/70\/6\/357\/5227738\/nutritionreviews70-0357.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,23]],"date-time":"2023-06-23T00:48:35Z","timestamp":1687481315000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/nutritionreviews\/article-lookup\/doi\/10.1111\/j.1753-4887.2012.00479.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5,30]]},"references-count":64,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,6]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1753-4887.2012.00479.x","relation":{},"ISSN":["0029-6643"],"issn-type":[{"value":"0029-6643","type":"print"}],"subject":[],"published":{"date-parts":[[2012,5,30]]}}}